No Data
No Data
Buy Rating Affirmed for Context Therapeutics Amid Strong Financials and Promising CLDN6-Targeting Therapies
Buy Rating Affirmed for Context Therapeutics as CTIM-76 Shows Promise and Strategic Team Expands Ahead of Clinical Trials
Context Therapeutics Q2 2024 Adj EPS $(0.04) Beats $(0.07) Estimate
Earnings Flash (CNTX) CONTEXT THERAPEUTICS Posts Q2 Loss $-0.04
Express News | Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Express News | Context Therapeutics Inc. Q2 Net Income USD -2.3 Million
No Data